Based on inducing hematologic and cytogenetic remissions in many patients with CML in chronic phase, IFN-α has been extensively used for CML patients treatment in an era [11], but it fails to effectively induce long-term cytogenetic remission in some CML patients [12]. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.